Levin I, Klein T, Kuperman O, Segal S, Shapira J, Gal R, Hart Y, Klein B
Department of Urology, Soroka Medical Center, Beer Sheva, Israel.
Cancer Detect Prev. 1994;18(6):443-5.
The expression of HLA class I antigens was studied using the immunoperoxidase technique on 30 patients with prostate cancer and 29 patients with benign prostatic hypertrophy (BPH). Forty-three percent of the tumors stained positive, in contrast to 21% of the BPH. An inverse relationship was noted between class I expression and degree of tumor differentiation: 88% of the well-differentiated tumors (8/9) expressed class I antigen, compared with 33% (3/9) of the moderately differentiated and 16% (2/12) of the poorly differentiated tumors. No significant survival difference was found between those with class I-positive and -negative tumors. However, when both class I expression and degree of differentiation were considered, those with positive tumors at each level of differentiation had better survival than those with negative tumors. These data suggest that HLA class I expression may serve as a finite prognostic factor and may have relevance in future immunotherapy.
采用免疫过氧化物酶技术对30例前列腺癌患者和29例良性前列腺增生(BPH)患者进行了HLA I类抗原表达的研究。43%的肿瘤呈阳性染色,相比之下,BPH患者中这一比例为21%。I类表达与肿瘤分化程度呈负相关:88%的高分化肿瘤(8/9)表达I类抗原,中分化肿瘤为33%(3/9),低分化肿瘤为16%(2/12)。I类阳性和阴性肿瘤患者之间未发现显著的生存差异。然而,当同时考虑I类表达和分化程度时,各分化水平的阳性肿瘤患者比阴性肿瘤患者的生存率更高。这些数据表明,HLA I类表达可能是一个有限的预后因素,并且可能与未来的免疫治疗相关。